These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34627624)

  • 1. Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.
    Giersing B; Shah N; Kristensen D; Amorij JP; Kahn AL; Gandrup-Marino K; Jarrahian C; Zehrung D; Menozzi-Arnaud M
    Vaccine; 2021 Dec; 39(49):7208-7219. PubMed ID: 34627624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations.
    Mvundura M; Frivold C; Janik Osborne A; Soni P; Robertson J; Kumar S; Anena J; Gueye A; Menozzi-Arnaud M; Giersing B; Kahn AL; Scarna T; Kristensen D
    Vaccine; 2021 Dec; 39(49):7195-7207. PubMed ID: 34412922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunities to accelerate immunization progress in middle-income countries.
    Zhu J; Cole CB; Fihman J; Adjagba A; Dasic M; Cernuschi T
    Vaccine; 2024 Apr; 42 Suppl 1():S98-S106. PubMed ID: 37460357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil.
    Pagliusi S; Dennehy M; Homma A
    Vaccine; 2020 Aug; 38(36):5851-5860. PubMed ID: 32535016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries.
    Ikilezi G; Augusto OJ; Dieleman JL; Sherr K; Lim SS
    Vaccine; 2020 Jan; 38(3):588-596. PubMed ID: 31679863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in vaccine investment in middle income countries.
    Onishchenko K; Hill S; Wasserman M; Jones C; Moffatt M; Ruff L; Pugh SJ
    Hum Vaccin Immunother; 2019; 15(10):2378-2385. PubMed ID: 30843757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential use of microarray patches for vaccine delivery in low- and middle- income countries.
    Peyraud N; Zehrung D; Jarrahian C; Frivold C; Orubu T; Giersing B
    Vaccine; 2019 Jul; 37(32):4427-4434. PubMed ID: 31262587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines, inspiring innovation in health.
    Pagliusi S; Dennehy M; Kim H;
    Vaccine; 2018 Nov; 36(48):7430-7437. PubMed ID: 29789241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A global collaboration to advance vaccine product innovations - The Vaccine Innovation Prioritisation Strategy.
    Kristensen D; Giersing B; Hickling J; Kazi F; Scarna T; Kahn AL; Hsu V; Gandrup-Marino K; Menozzi-Arnaud M
    Vaccine; 2021 Dec; 39(49):7191-7194. PubMed ID: 34175125
    [No Abstract]   [Full Text] [Related]  

  • 11. Controlled temperature chain for vaccination in low- and middle-income countries: a realist evidence synthesis.
    Seaman CP; Kahn AL; Kristensen D; Steinglass R; Spasenoska D; Scott N; Morgan C
    Bull World Health Organ; 2022 Aug; 100(8):491-502. PubMed ID: 35923285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
    Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
    PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges of vaccine presentation and delivery: How can we design vaccines to have optimal programmatic impact?
    Giersing BK; Kahn AL; Jarrahian C; Mvundura M; Rodriguez C; Okayasu H; Zehrung D
    Vaccine; 2017 Dec; 35(49 Pt A):6793-6797. PubMed ID: 28566254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-equity immunization and health systems strengthening strategies in select Gavi-supported countries.
    Dadari I; Higgins-Steele A; Sharkey A; Charlet D; Shahabuddin A; Nandy R; Jackson D
    Vaccine; 2021 Apr; 39(17):2434-2444. PubMed ID: 33781603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Middle-Income Countries Access to Vaccines. A Blueprint to Overcome Current Challenges.
    Espinal C; Becerra-Posada F; Torres JR
    Ann Glob Health; 2023; 89(1):80. PubMed ID: 38025920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges to sustainable immunization systems in Gavi transitioning countries.
    Cernuschi T; Gaglione S; Bozzani F
    Vaccine; 2018 Oct; 36(45):6858-6866. PubMed ID: 30268735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines.
    Neuzil KM; Bresee JS; de la Hoz F; Johansen K; Karron RA; Krishnan A; Madhi SA; Mangtani P; Spiro DJ; Ortiz JR;
    Vaccine; 2017 Oct; 35(43):5734-5737. PubMed ID: 28893473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
    Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
    Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating access for all through research and innovation in immunization: Recommendations from Strategic Priority 7 of the Immunization Agenda 2030.
    Sarley D; Hwang A; Fenton Hall B; Ford A; Giersing B; Kaslow DC; Wahl B; Friede M;
    Vaccine; 2024 Apr; 42 Suppl 1():S82-S90. PubMed ID: 36529593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities.
    Scarnà T; Menozzi-Arnaud M; Friede M; DeMarco K; Plopper G; Hamer M; Chakrabarti A; Gilbert PA; Jarrahian C; Mistilis J; Hesselink R; Gandrup-Marino K; Amorij JP; Giersing B
    Expert Opin Drug Deliv; 2023 Mar; 20(3):315-322. PubMed ID: 36649573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.